GH Secretagogue Approved (outside US)

Tesamorelin

Also known as: Egrifta, TH9507, Trans-3-hexenoic acid-GHRH(1-44)

A GHRH analog that stimulates natural pulsatile GH release — FDA-approved for lipodystrophy and widely used for visceral fat reduction and anti-aging.

Popularity A+
Class GHRH Analog
Half-Life 26-38 minutes
Form Lyophilized powder
Jump to Dosing ↓
Tesamorelin peptide vial used for visceral fat reduction research
Research-Backed User Reports Sourced Updated Mar 2026
// Overview

What is Tesamorelin?

Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification improves bioavailability and resistance to enzymatic degradation.

Unlike exogenous growth hormone (HGH), tesamorelin stimulates the body’s own pituitary gland to produce and release growth hormone in a pulsatile, physiological pattern. This preserves the natural feedback mechanisms that prevent excessive GH levels and associated side effects.

Originally developed and approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, tesamorelin has gained significant popularity in the anti-aging and body composition optimization community for its ability to increase GH levels, reduce visceral fat, and improve body composition without the risks of direct GH administration.

Found this helpful?

Join our newsletter for compound breakdowns, dosing protocols, and research updates.

Free forever. No spam. Unsubscribe anytime.

// How It Works

How Tesamorelin Works

Tesamorelin works by mimicking natural GHRH to stimulate the anterior pituitary gland:

  1. Pulsatile GH release — Binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering growth hormone synthesis and secretion in a natural pulsatile pattern.
  2. Preserved feedback loops — Unlike exogenous GH, tesamorelin maintains the hypothalamic-pituitary feedback axis. Somatostatin still regulates GH peaks, preventing supraphysiological spikes.
  3. Visceral fat reduction — GH-mediated lipolysis preferentially targets visceral adipose tissue. Clinical trials showed 15-18% reduction in trunk fat.
  4. IGF-1 elevation — Increased GH stimulates hepatic IGF-1 production, supporting tissue repair, collagen synthesis, and metabolic health.
// Dosage Protocols

Dosage Information (User-Reported)

Disclaimer: Dosage information is compiled from user reports and published research. This is not medical advice. Consult a healthcare professional before use.
Level Dose Frequency Duration
Standard 1-2 mg Once daily (before bed) 3-6 months
Anti-Aging Protocol 1 mg Once daily 6-12 months
Body Composition 2 mg Once daily 3-6 months

What to Expect

Week 1-2

Improved sleep quality often reported first. Mild injection site reactions possible. No immediate body composition changes yet.

Week 3-6

Sleep deepens further. Skin quality begins improving. Some users report increased energy and recovery.

Month 2-3

Measurable fat loss becomes apparent, particularly around midsection. Improved workout recovery. Better hair and nail growth.

Month 3-6

Peak body composition changes. 10-15% visceral fat reduction typical. Skin elasticity visibly improved. Enhanced exercise capacity.

Common Stacks

Ipamorelin

Amplified GH Pulse

GHRH + GHRP synergy produces larger GH pulses than either alone

BPC-157

Recovery Enhancement

Accelerates tissue healing alongside GH-mediated repair

CJC-1295 no DAC

Extended GH Release

Pairs GHRH analog with modified GHRH for sustained GH elevation

// Preparation

Reconstitution & Storage

Reconstitute with bacteriostatic water (BAC water). For a typical 2mg vial, add 2mL BAC water for 1mg/mL concentration.

Inject water slowly down the side of the vial. Do not shake — gently swirl until fully dissolved. Solution should be clear and colorless.

Store reconstituted vial refrigerated (2-8°C). Use within 14 days.

Storage: Lyophilized: room temperature. Reconstituted: refrigerate 2-8°C, use within 14 days.
// Safety Profile

Side Effects & Safety

Potential Side Effects

  • ! Injection site reactions (redness, swelling)
  • ! Joint pain or stiffness
  • ! Fluid retention / edema
  • ! Paresthesia (tingling in extremities)
  • ! Headache
  • ! Nausea
  • ! Elevated fasting glucose (monitor if pre-diabetic)

Contraindications

  • ⚠ Active malignancy (GH may stimulate tumor growth)
  • ⚠ Hypersensitivity to tesamorelin or mannitol
  • ⚠ Pregnancy
  • ⚠ Disruption of hypothalamic-pituitary axis (e.g., from surgery, radiation, or trauma)

Legal & Regulatory Status

FDA-approved as Egrifta for HIV-associated lipodystrophy. Prescription-only for approved indication. Research-grade tesamorelin available from peptide vendors for research purposes. Not a controlled substance.

// Research

Published Research

// Related Compounds

Other GH Secretagogue Guides

Selank peptide nasal spray used for anxiolytic and nootropic research

Selank

A clinically approved anxiolytic peptide offering benzodiazepine-level anxiety relief without sedation, addiction, or cognitive impairment — plus immune…

Read Guide →
Athome blood test kit with fingerprick lancet and collection card for biomarke

Thymosin Alpha 1

A thymic peptide approved in 35+ countries that restores and enhances adaptive immunity — T-cell maturation, antiviral defense,…

Read Guide →
Highresolution illustration of neural pathways lighting up during cognitive enh

VIP

A master regulatory neuropeptide with broad anti-inflammatory, vasodilatory, and neuroprotective effects — critical in mold illness (CIRS) treatment…

Read Guide →

Stay informed on Tesamorelin.

New research, dosage updates, and protocol breakdowns. Straight to your inbox.

Free forever. No spam. Unsubscribe anytime.

This content is for informational and educational purposes only. Tesamorelin is sold for research purposes. Never Natty does not condone or encourage the use of any substance in violation of any laws. Consult a healthcare professional before using any compound discussed on this site.